Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Infographic: RA Perceptions

August 25, 2015 | Biologics, physicians, rheumatoid arthritis 

HCPs predict the future of the biologics market

Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.

Download our RA Perceptions: Predicting the future of the European market infographic now »

RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.

Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.

Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.

Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.

The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Webinar: Mobile Research in Asia and Emerging Markets

Current statistics around mobile technology reveal that many physicians in Asia are now using smartphones, tablets and other mobile devices to assist them in their daily practices. In China alone,73%...

Webinar: Understanding the Patient Journey in Order to Influence Prescribing Decisions

Using real data, this webinar looks at the increasingly popular view that says we need to understand more about the patient and the relationship they have with their physicians in...

Webinar: Focus on China: Conducting Research in the World’s Fastest Growing Pharma Market

This webinar looks to provide market research professionals with an overview of the Chinese healthcare market and provide participants with top tips for conducting relevant and effective market research in...

Webinar: Prescription Rationale: Physician Research via an iPhone App

This webinar explores the potential of using smartphone Apps as a platform for collecting detailed qualitative insights into physicians' decision rationale at the moment of prescription.

Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

Director Marc Yates looks at the problem of patient compliance - can a better understanding of patient attitudes, needs and behaviours help pharma develop strategies to improve adherence?

Digital research in Asia

Director Marc Yates uses findings from a study conducted in six markets in Asia to explore how digital channels are being utilised by consumers and look at the digital opportunities...

Achieving customer centricity – Using immersion techniques to get closer to the pulse of the customer

Director Marc Yates discusses the importance of being customer-centric in the pharmaceutical industry and how immersion techniques in market research can help develop a better understanding of the customer.

The Mobile Revolution – Using mobile Apps to deliver “in-the-moment” market research to global healthcare

Director John Branston investigates the use of mobile research in order to capture immediate detailed, qualitative insights into prescription rationale at the patient level.